Author:
Götz Mario E.,Riederer Peter
Reference178 articles.
1. M. Gerlach, P. Riederer, M. B. Youdim, Neuroprotective therapeutic strategies, comparison of experimental and clinical results, Biochem. Pharmacol. 50(1), 1–16 (1995).
2. E. Grün blatt, R. Schlö ßer, M. Gerlach, and P. Riederer, Preclinical versus clinical neuroprotection, in Parkinson’s disease: Advances in Neurology 91, edited by A. Gordin, S. Kaakkola, and H. Teräväinen (Lippincott Williams & Wilkins, Philadelphia, 2003), pp. 309–328.
3. C. E. Clarke, and M. Guttman, Dopamine agonist monotherapy in Parkinson’s disease, Lancet 360(9347), 1767–1769 (2002).
4. W. Birkmayer, P. Riederer, L. Ambrozi, and M. H. Youdim, Implications of combined treatment with “Madopar“ and L-deprenyl in Parkinson’s disease; A long-term study, Lancet 1(8009), 439–443 (1977).
5. J. Knoll, J. Dallo, and, T.T. Yen, Striatal dopamine, sexual activity and lifespan, Longevity of rats treated with (-) deprenyl, Life Sci. 45(6), 525–531 (1989).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献